Social Responsibility

Our Social Impact: Helping people around the world.

Social topics like talent recruitment, retainment and training as well as access to medicine have a high importance for the whole pharmaceutical sector.

Concerning product safety risks (side-effects), our business model leads to reduced risks due to the long track record of our products. And with products sold to patients in more than 120 countries in the world, we help sick persons with a wide variety of indications, including rarer diseases, while our lower-cost off-patent products help deliver savings to healthcare systems worldwide.

Our committment to our employees

As of March 31, 2021, Cheplapharm employs a workforce of 428 people. In 2020, Cheplapharm employed people from 24 different countries (2019: 15 countries).

Equal chances for employed women and men are a priority topic for Cheplapharm. This is why we foster a family-friendly working environment. Part-time models and flexible working hours are a matter of course to allow for a reconciliation of work and family. We furthermore actively prepare women for leadership positions by providing leadership trainings. Through these efforts, Cheplapharm currently features a workforce that is at 56% more female than other pharmaceutical companies in Germany (41%1) and currently features 45% women in leadership positions2, way above the average across all industries in Germany (29%3).

To retain talented employees, Cheplapharm initiated a companywide talent management system that includes targeted training measures. One example is a leadership development training program in cooperation with external coaches that has to be completed by all team leaders.

To further help develop the organization as a whole, the involvement of our employees is very important to us. Employees can be part of an employee working group that allows them to provide feedback and improvement proposals to the management. In 2020 we furthermore asked our employees in a survey to gauge the quality of leadership in their teams – the results are being processed and turned into improvements.

In 2020, the fluctuation rate sank to 11.4% after 15.6% in 2019. The share of part-time contracts also declined to 7.2% (2019: 8.5%). 

SOCIAL INDICATOR20192020
Number of employees292377
Proportion of part-time employees8,5 %7,2 %
Total proportion of women58,6 %56,8 %
Share of women in leadership positions (Management Board, Directors, Teamleaders)-45 %
Fluctuation rate15,6%11,4 %
Recall quota (in % of all batches)-0,03 %
Quality is our highest priority

Providing pharmaceutical products to millions of patients around the globe Cheplapharm is acutely aware of its responsibility to provide safe and reliable products. Therefore, our company currently employs over 60 people in its quality assurance department, following an established Quality Management System that includes a thorough CAPA management. Cheplapharm also strictly adheres to internationally valid Good Manufacturing Practice (GMP) and Good Distribution Practices (GDP) for the pharmaceutical industry. 

Social Responsibility in the supply chain

Of the suppliers who answered in our initial supplier survey, 79%4  reported that they followed a quality management standard according to HACCP, ISO 9001 or equivalent. 93%5  of the suppliers offered regular employee trainings on employee and product safety in the production. 86%6  furthermore had detailed policies in place that prohibit child and forced labor in their supply chain, while 93%7  indicated that they had a grievance management system in place through which employees could voice their complaints and provide improvement proposals.


1 www.vfa.de/de/wirtschaft-politik/wirtschaft/frauen-fuehren-ein-drittel-der-forschenden-pharma-unternehmen-in-deutschland
2 Defined as members of the Management Board (Level 1), Directors (Level 2) and Team Leaders (Level 3)
3 www.destatis.de/DE/Themen/Arbeit/Arbeitsmarkt/Qualitaet-Arbeit/Dimension-1/frauen-fuehrungspositionen.html
4 Corresponding to a total buy volume of 27.67%
5 Corresponding to a total buy volume of 28.21%
6 Corresponding to a total buy volume of 23.54%
7 Corresponding to a total buy volume of 26.03%